PMID: 9449270Feb 4, 1998Paper

Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily

Antimicrobial Agents and Chemotherapy
S ChodoshS A Breisch

Abstract

A randomized, prospective, double-blind, double-dummy, multicenter study investigated the efficacy and safety of 10 days of oral therapy with grepafloxacin at 400 mg once daily, grepafloxacin at 600 mg once daily, or ciprofloxacin at 500 mg twice daily in 624 patients with acute bacterial exacerbations of chronic bronchitis. At the end of treatment, clinical success (cure or improvement) was achieved for 93% (140 of 151), 88% (137 of 156), and 91% (145 of 160) of patients in the groups receiving grepafloxacin at 400 mg, grepafloxacin at 600 mg, and ciprofloxacin, respectively (clinically evaluable population). At follow-up (14 to 28 days posttreatment), the clinical success rates were 87% (124 of 143), 81% (122 of 151), and 80% (123 of 154) in the groups receiving grepafloxacin at 400 mg and 600 mg and ciprofloxacin, respectively. A total of 379 pathogens were isolated from 290 patients, with the most common isolates being Moraxella catarrhalis (21%), Staphylococcus aureus (20%), Haemophilus influenzae (18%), and Streptococcus pneumoniae (7%). For the evaluable population, successful bacteriologic response was obtained at the end of treatment for 96% (92 of 96), 98% (87 of 89), and 92% (82 of 90) of patients receiving grepaflox...Continue Reading

References

Mar 1, 1992·Antimicrobial Agents and Chemotherapy·T ImadaS Goto
Apr 1, 1992·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H S SaderR N Jones
Jun 1, 1992·Antimicrobial Agents and Chemotherapy·H C NeuN X Chin
Jul 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P C Appelbaum
Dec 30, 1991·The American Journal of Medicine·S Chodosh
Apr 1, 1986·European Journal of Clinical Microbiology·B I DaviesC Baur
Feb 1, 1995·The Journal of Antimicrobial Chemotherapy·P J CookH Moudgil
Jan 1, 1994·The Pediatric Infectious Disease Journal·F Baquero, E Loza
Apr 1, 1993·The Journal of Antimicrobial Chemotherapy·R WiseN Brenwald
Sep 1, 1996·Diagnostic Microbiology and Infectious Disease·P C FuchsS D Brown
Nov 1, 1993·International Journal of Antimicrobial Agents·P Cole

❮ Previous
Next ❯

Citations

Nov 30, 2000·Current Infectious Disease Reports·P Ball
Jan 31, 2006·Expert Review of Anti-infective Therapy·Fernando J MartinezJeffrey Curtis
Jun 9, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert C Owens, Paul G Ambrose
May 21, 1998·Antimicrobial Agents and Chemotherapy·G A PankuchP C Appelbaum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.